Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lynparza
Pharma
Keytruda-Lynparza combo scores tepid win in ovarian cancer trial
After flunking three clinical trials with a Keytruda-Lynparza combo, Merck has emerged with a tepid win for the regimen in an ovarian cancer study.
Kevin Dunleavy
Dec 9, 2024 11:18am
Pfizer targets broad Talzenna label in prostate cancer
Oct 10, 2024 10:18am
Where's Lynparza in AZ's narrow Imfinzi endometrial cancer nod?
Jun 17, 2024 11:24am
AACR: Detailed data spark hope for Merck combo in NSCLC
Apr 9, 2024 1:16pm
Merck’s Lynparza-Keytruda plan sputters in 2nd lung cancer trial
Mar 21, 2024 10:28am
AZ, GSK make case for broad I-O uses in endometrial cancer
Mar 18, 2024 11:05am
